Acceleron Pharma Inc. (XLRN) financial statements (2022 and earlier)

Company profile

Business Address 128 SIDNEY STREET
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments850882390414431426431
Cash and cash equivalents671730284277238170164
Short-term investments179153106137194257267
Receivables2623408975
Other undisclosed current assets179199101110
Total current assets:893914449432450444446
Noncurrent Assets
Operating lease, right-of-use asset22202123242527
Property, plant and equipment8887777
Long-term investments and receivables85 1224270
Long-term investments85 1224270
Other noncurrent assets2222200
Other undisclosed noncurrent assets     22
Total noncurrent assets:393430325576105
TOTAL ASSETS:932948479464505520551
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities53313122272620
Accounts payable89134224
Accrued liabilities45221818252417
Debt   6666
Other undisclosed current liabilities776    
Total current liabilities:60373729333226
Noncurrent Liabilities
Long-term debt and lease obligation17151719202223
Operating lease, liability17151719202223
Liabilities, other than long-term debt     00
Other liabilities     00
Other undisclosed noncurrent liabilities(17)(15)(13)3211
Total noncurrent liabilities: 152022222325
Total liabilities:77535850555551
Stockholders' equity
Stockholders' equity attributable to parent855895422414449465500
Common stock0000000
Additional paid in capital1,7331,7151,2021,1761,1611,1521,142
Accumulated other comprehensive income (loss)(0)(0)(0)(0)000
Accumulated deficit(877)(820)(781)(762)(711)(688)(642)
Total stockholders' equity:855895422414449465500
TOTAL LIABILITIES AND EQUITY:932948479464505520551

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Gross profit:262340439428
Operating expenses(83)(62)(59)(56)(65)(53)(49)
Operating loss:(58)(39)(19)(52)(26)(49)(21)
Nonoperating income (expense)0(0)01243
Other undisclosed income from continuing operations before equity method investments, income taxes0   0  
Loss from continuing operations before equity method investments, income taxes:(57)(39)(18)(51)(24)(45)(18)
Other undisclosed loss from continuing operations before income taxes(0)   (0)  
Loss from continuing operations before income taxes:(57)(39)(18)(51)(24)(45)(18)
Income tax expense (benefit)0(0)(0)(0)000
Net loss available to common stockholders, diluted:(57)(39)(18)(51)(24)(45)(18)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(57)(39)(18)(51)(24)(45)(18)
Comprehensive loss:(57)(39)(18)(51)(24)(45)(18)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)(0)0(0)(0)(0)0
Comprehensive loss, net of tax, attributable to parent:(57)(39)(18)(51)(24)(45)(17)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: